Form 4: BridgeBio Pharma Director Ronald J. Daniels Receives Significant Equity Compensation

BridgeBio Pharma, Inc. Director Ronald J. Daniels was granted 6,589 restricted stock units and 8,425 stock options as part of his compensation, aligning his interests with shareholders.

Summary

• Ronald J. Daniels, a Director of BridgeBio Pharma, Inc. (BBIO), reported changes in his beneficial ownership of company securities.
• On June 20, 2025, Mr. Daniels was granted 6,589 Restricted Stock Units (RSUs) under the Issuer's 2021 Amended and Restated Stock Option and Incentive Plan.
• Each RSU represents a contingent right to receive one share of BridgeBio Pharma's Common Stock.
• One-third of these RSUs will vest annually after June 20, 2025, with full vesting by June 20, 2028, contingent on his continued service on the board.
• Additionally, Mr. Daniels acquired 8,425 stock options with an exercise price of $41.73 per share on June 20, 2025.
• Similar to the RSUs, one-third of the shares underlying these stock options will vest annually after June 20, 2025, fully vesting by June 20, 2028, subject to his continued board service.
• The stock options have an expiration date of June 19, 2035.
• Following these transactions, Mr. Daniels directly beneficially owns 16,991 shares of Common Stock and 8,425 stock options.
• The transaction was made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. It's a routine compensation grant, which is a positive for aligning director interests with shareholders, but it doesn't indicate any new operational or financial performance.

Positives

• The grant of RSUs and stock options to a director aligns management's interests with those of shareholders, as the value of his compensation is tied to the company's stock performance.
• The use of a Rule 10b5-1 plan indicates a pre-arranged, systematic approach to equity transactions, reducing concerns about opportunistic insider trading.

Risks

• The vesting of both RSUs and stock options is subject to the Reporting Person's continued service on the Issuer's board of directors, meaning the compensation is not guaranteed if his service ceases before the vesting dates.

Future Outlook

The future outlook for the reporting person's equity holdings includes the vesting of restricted stock units and stock options in one-third increments annually, with full vesting expected by June 20, 2028, provided continued service on the board.

Management Comments

• "/s/ Ronald J. Daniels" (Signature of Reporting Person)

Industry Context

This filing represents a routine equity compensation grant to a director, a common practice across industries, including the biotechnology and pharmaceutical sectors, to incentivize long-term commitment and align leadership interests with shareholder value.

Corporate Governance

Related Party Transactions

• The grant of restricted stock units and stock options to Ronald J. Daniels, a director of BridgeBio Pharma, Inc., constitutes a related party transaction as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The equity grants align the director's financial interests with the company's stock performance, potentially encouraging decisions that enhance shareholder value.
• Employees: While not directly impacting general employees, such compensation practices for directors reflect the company's overall approach to incentivizing key personnel.

Next Steps

• Vesting of the granted 6,589 RSUs will occur in one-third increments annually after June 20, 2025, until fully vested on June 20, 2028.
• Vesting of the granted 8,425 stock options will occur in one-third increments annually after June 20, 2025, until fully vested on June 20, 2028.
• Ronald J. Daniels' continued service on the BridgeBio Pharma board of directors is required for the vesting of these equity awards.

Key Dates

Keywords

BridgeBio Pharma, BBIO, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Options, Equity Compensation, Director Compensation, Beneficial Ownership, Rule 10b5-1 Plan